AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35056316
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of SCS and DRGS (SCS+DRGS)
Trial: 32704082
Drug: Nutritional support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional support plus green-banana biomass (40 g) (n=21)
Trial: 33400390
Drug: UC-MSC treatment
RxNorm normalized name: Astri-UC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UC-MSC treatment (100 ± 20 × 10^6 UC-MSCs, two intravenous infusions at day 0 and 3)
Trial: 33400390
Drug: Control (vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (vehicle solution, two infusions)
Trial: 35711442
Drug: bivalent Oral
RxNorm normalized name: Non-US bivalent oral polio vaccine (types 1 and 3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bivalent Oral Poliovirus Vaccine (bOPV)
Trial: 33550679
Drug: Preparation for
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation for the TSST‐M alone
Trial: 33550679
Drug: Preparation for
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation for the TSST‐M with a parent
Trial: 32114186
Drug: Enhanced treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced treatment (5 worksites; n = 50 participants)
Trial: 32114186
Drug: Minimal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal treatment (3 worksites; n = 47 participants)
Trial: 32114186
Drug: Both enhanced
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both enhanced and minimal treatment
Trial: 34337726
Drug: Parecoxib 40
RxNorm normalized name: Parécoxib
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Parecoxib 40 mg IV 30 min before surgery and then 40 mg IV every 12 h for the initial 48 h postoperatively (n=20)
Trial: 33945983
Drug: Feedback-informed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Feedback-informed treatment (FIT)
Trial: 38721015
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (C)
Trial: 35407572
Drug: Mosapride SR
RxNorm normalized name: mosapride
DrugBank: Mosapride (DB11675)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mosapride SR 15 mg combined with esomeprazole 20 mg once daily (ME group)
Trial: 35407572
Drug: Esomeprazole 20
RxNorm normalized name: esomeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 20 mg once daily alone (E group)
Trial: 32062494
Drug: PG54 (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PG54 (n = 434), administered prostaglandin F2α (25 mg im) 7 days prior to TAI
Trial: 32062494
Drug: PG72 (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PG72 (n = 426), same treatment as PG54 but TAI performed 72 ± 2 h after CIDR removal
Trial: 35507901
Drug: no treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no treatment (NC)
Trial: 37259053
Drug: Aripiprazole once-monthly
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aripiprazole once-monthly (AOM) treatment for 6 months
Trial: 35897358
Drug: LLLT (Low-Level
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LLLT (Low-Level Laser Therapy)
Trial: 38324741
Drug: Intensive chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive chemotherapy alone (control group)
Trial: 32183897
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual with awareness of the patient guideline
Trial: 34800989
Drug: verum occipital
RxNorm normalized name: Cinnamomum verum whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: verum occipital tDCS treatment for 28 days
Trial: 34800989
Drug: sham occipital
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sham occipital tDCS treatment
Trial: 32316911
Drug: Lovastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin (10 to 40 mg/day)
Trial: 34857640
Drug: Prophylactic dextrose
RxNorm normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic dextrose gel
Trial: 34857640
Drug: No gel
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No gel (controls)
Trial: 35966875
Drug: Sitagliptin 50
RxNorm normalized name: SITagliptin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 50 mg daily for 56 weeks
Trial: 34609058
Drug: Sandwich osteotomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sandwich osteotomy with simultaneous implant placement using patient-specific guides (PSGs)
Trial: 32239737
Drug: Nerve stimulator-guided
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nerve stimulator-guided injection with methylprednisolone/lidocaine
Trial: 33740736
Drug: Platelet-rich plasma
RxNorm normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet-rich plasma (PRP) gel, applied twice weekly for 3 weeks
Trial: 33740736
Drug: Conventional dressing
RxNorm normalized name: DRESSING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dressing with silver sulfadiazine ointment, applied twice daily
Trial: 32543876
Drug: Manual Physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual Physical Therapy (MPT)
Trial: 32543876
Drug: Conventional Pharmacologic
RxNorm normalized name: COPD pharmacologic substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Pharmacologic Treatment (CPT)
Trial: 34720019
Drug: Clonidine (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (0.1 mg) tablet given twice a day for two months
Trial: 33682556
Drug: ZSP1601 (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZSP1601 (25 to 350 mg single ascending dose)
Trial: 33682556
Drug: ZSP1601 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZSP1601 (50 or 100 mg QD multiple ascending doses)
Trial: 33682556
Drug: ZSP1601 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZSP1601 (100 mg)
Trial: 32274634
Drug: GM-CSF (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM-CSF (2 ng/ml)
Trial: 616788547
Drug: Exercise +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise + L-carnitine
Trial: 616788547
Drug: Exercise +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise + Omega-3 + L-carnitine
Trial: 616788547
Drug: L-carnitine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine + Omega-3
Trial: 35065662
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of intravenous (IV) phenobarbital (7.5 mg/kg of ideal body weight)
Trial: 35065662
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of matching IV placebo
Trial: 34400314
Drug: Intermittent high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent high-dose ICS without use of background controller
Trial: 34400314
Drug: As-needed ICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As-needed ICS dosing
Trial: 32912290
Drug: Ibudilast (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibudilast (50 mg BID)
Trial: 33487257
Drug: Regular yogurt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular yogurt (300 g/d)
Trial: 32607569
Drug: Early oral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early oral hydration (ice chips and water) after extubation
Trial: 35498440
Drug: Testosterone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone (10 mg/day)
Trial: 34872283
Drug: 0.05 µg·kg‐1·min‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 µg·kg‐1·min‐1 remifentanil combined with sevoflurane
Trial: 34872283
Drug: 0.1 µg·kg‐1·min‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 µg·kg‐1·min‐1 remifentanil combined with sevoflurane
Trial: 34215501
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment plus tailored exercise training (foam dressing, short-stretch bandage, stretching, resistive, and aerobic exercise sessions, 3 days/week for 12 weeks)
Trial: 34215501
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment alone (foam dressing, short-stretch bandage)
Trial: 34215501
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment plus tailored exercise training
Trial: 32198520
Drug: Mailed nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mailed nicotine replacement therapy (NRT)
Trial: 36154908
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg CBD Isolate
Trial: 36154908
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg CBD Broad Spectrum
Trial: 33707768
Drug: Protein drug
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein drug targets
Trial: 33707768
Drug: Drug targets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug targets
Trial: 35722465
Drug: rCCK96‐104PE38 targeted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rCCK96‐104PE38 targeted drug
Trial: 34533039
Drug: Glutathione infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutathione infusion (2500 mg/25 mL over 10 minutes, followed by the same doses at 24, 48, and 72 hours)
Trial: 35531796
Drug: PN-HPT® (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PN-HPT® (4 ml intradermally)
Trial: 35531796
Drug: Cross-linked hyaluronic
RxNorm normalized name: riboflavin 5'-phosphate
DrugBank: Flavin mononucleotide (DB03247)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cross-linked hyaluronic acid (2 ml subdermally)
Trial: 35531796
Drug: Saline (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (4 ml intradermally)
Trial: 32909076
Drug: ebselen (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ebselen (600 mg bd)
Trial: 35686561
Drug: Ramipril 2.5
RxNorm normalized name: ramipril 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril 2.5 mg once daily for 16 weeks
Trial: 33608976
Drug: Dialectical behavior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialectical behavior therapy for adolescents + brief cognitive intervention to decrease self-criticism
Trial: 32866634
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) using eosin
Trial: 35381840
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine infusion (IV group)
Trial: 33200626
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (500 mg elemental calcium daily until 20 weeks' gestation, then 1.5 g until delivery)
Trial: 35829749
Drug: Treatment in
RxNorm normalized name: Other agents for local oral treatment in ATC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment in MRI
Trial: 35829749
Drug: Last fraction
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Last fraction of treatment
Trial: 35012812
Drug: Phenylephrine 100 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine 100 μg
Trial: 35012812
Drug: Norepinephrine 8 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine 8 μg
Trial: 32434847
Drug: PfSPZ-GA1 Vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PfSPZ-GA1 Vaccine (9.0 × 10^5 PfSPZ)
Trial: 32434847
Drug: PfSPZ-GA1 Vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PfSPZ-GA1 Vaccine (4.5 × 10^5 PfSPZ)
Trial: 32434847
Drug: PfSPZ Vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PfSPZ Vaccine (4.5 × 10^5 PfSPZ)
Trial: 32434847
Drug: PfSPZ-GA1 Vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PfSPZ-GA1 Vaccine (both doses)
Trial: 37431294
Drug: asciminib 40
RxNorm normalized name: asciminib 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: asciminib 40 mg twice daily
Trial: 34407542
Drug: bosutinib 500
RxNorm normalized name: bosutinib 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bosutinib 500 mg once daily
Trial: 32034814
Drug: Amlodipine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (5 mg) from Fangming Pharmaceutical Group (Test, T)
Trial: 32034814
Drug: Amlodipine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (5 mg) from NORVASC® (Reference, R)
Trial: 38814433
Drug: Ixekizumab (IXE)
DrugBank: Ixekizumab (DB11569)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ixekizumab (IXE) 80 mg every 2 weeks (Q2W)
Trial: 38814433
Drug: Ixekizumab (IXE)
DrugBank: Ixekizumab (DB11569)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ixekizumab (IXE) 80 mg every 4 weeks (Q4W)
Trial: 32384434
Drug: Acupoint catgut
RxNorm normalized name: CATGUT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint catgut embedding treatment (two weeks at predefined acupuncture points: Shenshu (BL23), Sanyinjiao (SP6), Guanyuan (RN4), Ganshu (BL18), Zusanli (ST36), Pishu (BL20))
Trial: 32384434
Drug: Alprazolam tablet
RxNorm normalized name: Alprazolam Tablets
DrugBank: Alprazolam (DB00404)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alprazolam tablet (0.4 mg, 1 tablet, 3 times a day)
Trial: 33706003
Drug: Bupropion XL
RxNorm normalized name: Bupropion Hydrochloride 150 MG Oral Tablet, Extended Release [BUPROPION XL]
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupropion XL 300 mg/day
Trial: 34654402
Drug: Radiotherapy comprising
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiotherapy comprising 25 Gy in 5 fractions with concomitant (150 mg/m2/day, 5 days) and adjuvant temozolomide
Trial: 34654402
Drug: Radiotherapy comprising
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiotherapy comprising 40 Gy in 15 fractions with concomitant (75 mg/m2/day, every day from first to last day of radiation) and adjuvant temozolomide
Trial: 35387783
Drug: BCT plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCT plus ultrasound guided intra‐articular hip injection of 40 mg triamcinolone acetonide and 4 mL 1% lidocaine
Trial: 35387783
Drug: BCT plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCT plus ultrasound guided intra‐articular hip injection of 5 mL 1% lidocaine
Trial: 35387783
Drug: BCT (best
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCT (best current treatment)
Trial: 35640099
Drug: Oral-Silent-Oral (OSO)
RxNorm normalized name: Silene laciniata whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral-Silent-Oral (OSO) condition
Trial: 35640099
Drug: Silent-Oral (SO)
RxNorm normalized name: Silene laciniata whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silent-Oral (SO) condition
Trial: 35986465
Drug: Phos‐Flur gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phos‐Flur gel (study group)
Trial: 32297054
Drug: Laparoscopically guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laparoscopically guided TAP block with 10 ml of 0.25% bupivacaine at each of the four sites
Trial: 33687487
Drug: PB-119 75
RxNorm normalized name: PB-722
DrugBank: PB-722 (DB18447)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PB-119 75 μg
Trial: 33687487
Drug: PB-119 150
RxNorm normalized name: PB-722
DrugBank: PB-722 (DB18447)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PB-119 150 μg
Trial: 33687487
Drug: PB-119 200
RxNorm normalized name: PB-722
DrugBank: PB-722 (DB18447)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PB-119 200 μg
Trial: 35853272
Drug: Pre-operative sublingual
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pre-operative sublingual 400mcg misoprostol
Trial: 35704338
Drug: Very low
RxNorm normalized name: Very low fat spread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very low nicotine content cigarettes (0.4 mg/g nicotine)
Trial: 32520577
Drug: Norepinephrine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine infusion in LPS-challenged volunteers
Trial: 32520577
Drug: Higher norepinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher norepinephrine infusion rates in patients
Trial: 32520577
Drug: β-blocker use
RxNorm normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: β-blocker use in patients
Trial: 35838942
Drug: Melatonin (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (0.3 mg/kg for < 10 kg, 3 mg for 10-15 kg, 6 mg for > 15 kg)
Trial: 35838942
Drug: Triclofos (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triclofos (50 mg/kg, max 1 g for 6 mo to 11 y; 2 g for 11 to 18 y)
Trial: 34370612
Drug: Nonimmersive virtual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonimmersive virtual reality (VR) intervention associated with conventional therapy
Trial: 35999816
Drug: Patient engagement
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient engagement strategies including bi-weekly meetings, newsletters, and educational materials.
Trial: 36306132
Drug: 2.4 g
RxNorm normalized name: ZINC OXIDE 12.4 g in 100 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.4 g intravenous casirivimab and imdevimab
Trial: 36306132
Drug: 8.0 g
RxNorm normalized name: PERACETIC ACID 8.0 g in 4000 mL TOPICAL LIQUID [Peraflu D]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8.0 g intravenous casirivimab and imdevimab
Trial: 34519801
Drug: Camrelizumab plus
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camrelizumab plus chemotherapy (paclitaxel 175 mg/m2 and cisplatin 75 mg/m2)
Trial: 34519801
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus chemotherapy (paclitaxel 175 mg/m2 and cisplatin 75 mg/m2)
Trial: 35377447
Drug: Lanraplenib 30
RxNorm normalized name: Lanraplenib
DrugBank: Lanraplenib (DB14770)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanraplenib 30 mg
Trial: 35377447
Drug: Tirabrutinib 40
RxNorm normalized name: Tirabrutinib
DrugBank: Tirabrutinib (DB15227)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirabrutinib 40 mg
Trial: 35329211
Drug: Weekly content
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly content with customised behaviour change techniques (experimental group)
Trial: 32667902
Drug: Saline consumption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline consumption (423 mL of normal saline, sodium 154 mmol/L)
Trial: 33622669
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg TTP399
Trial: 33464300
Drug: Atabecestat 25
RxNorm normalized name: Atabecestat
DrugBank: Atabecestat (DB15307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atabecestat 25 mg
Trial: 33464300
Drug: Atabecestat (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atabecestat (5 mg and 25 mg)
Trial: 33464300
Drug: Follow-up after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Follow-up after stopping treatment
Trial: 35584268
Drug: Corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid injection with splint (40 mg methylprednisolone + 0.5 ml lidocaine, splint worn full time for 3 months)
Trial: 35584268
Drug: Corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid injection without splint (40 mg methylprednisolone + 0.5 ml lidocaine)
Trial: 35027324
Drug: HAI-ox with
RxNorm normalized name: OX BILE
DrugBank: Ox bile extract (DB14016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAI-ox with FOLFOX + targeted therapy or FOLFOXIRI + bevacizumab
Trial: 35027324
Drug: Systemic oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Systemic oxaliplatin with FOLFOX + targeted therapy or FOLFOXIRI + bevacizumab
Trial: 34271948
Drug: Multifactorial intensive
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multifactorial intensive therapy (MT)
Trial: 35274344
Drug: Home-based oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based oral exercises (tongue-strengthening, oral diadochokinesis, mouth-opening exercises) for 3 months